Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Dose Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
We often hear of the need for an “elevator pitch” in the context of raising capital – a brief 30-second persuasive speech to spark...
We often hear of the need for an “elevator pitch” in the context of raising capital – a brief 30-second persuasive speech to spark...
/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...